Navigation Links
PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012
Date:9/18/2009

INCLINE VILLAGE, Nev., Sept. 18 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the "Notes"). The conversion rate, as adjusted, is 94.447 shares of common stock per $1,000 principal amount of the Notes, effective September 18, 2009. The conversion rate for the Notes was previously 89.165 shares of common stock per $1,000 principal amount of the Notes.

On March 2, 2009, PDL announced a cash dividend of $0.50 per share of its common stock, payable to stockholders of record on September 17, 2009. In connection with the cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding September 15, 2009, the ex-dividend date for the cash dividend, and the denominator of which is the difference of such average closing price less $0.50.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering
2. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
3. Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
4. Helix BioPharma Closes Private Placement
5. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
6. Helix BioPharma Announces $13.5 Million Private Placement
7. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
8. DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
9. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
10. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... NineSigma , Inc., of Cleveland , ... NineSights.com is now the innovation engine for the ... of innovators. From technology developers, to chemical ... out for its large community of innovators in an ... vetted by NineSigma. The community is free to join ...
(Date:6/19/2013)... 2013 Today DuPont Executive Vice President ... become leaders in the greatest challenge facing our time ... 2050. Borel spoke at the International Food ... about urgent need for students to contribute their time ... sustainable and reached in collaboration with others. , “Food ...
(Date:6/19/2013)... , June 19, 2013 ... Book Bureau presents Innovative Drug ... Formulation Technology Licensing Opportunities for ... ) There are ... controlled release drugs approved all ...
(Date:6/19/2013)... India’s vast and growing population ... worth up to a billion dollars per year ... is taking serious action to better regulate and ... presentation will examine:, ,     Recent changes ... and long term impacts ,     Foreseeable opportunities ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... Executive Chairman and CFO Assume Leadership Responsibilities; CEO Search ... ... Calif., Jan. 30 Genelabs,Technologies, Inc. (Nasdaq: GNLB ) announced ... Officer and Director of the,company, effective January 29, 2008. Irene A. ...
... BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864), ... BioPharma Corp.,announces that at the Company,s Annual General ... of the resolutions presented by,management, appointing KPMG LLP ... Jack Kay, Slawomir Majewski, and Gordon Lickrish as,directors, ...
... Fla., Jan. 30 John Wagner, M.D., recognized as,a ... transplantation, has joined,the team at CORD:USE Cord Blood Bank. ... stem cell biology will provide a,significant contribution to CORD:USE., ... a member of our,distinguished team," says Edward Guindi, M.D., ...
Cached Biology Technology:Genelabs Technologies, Inc. Announces Resignation of President and CEO 2Helix BioPharma shareholders vote in favour of management 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 3
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... for Molecular Pathology is proud to announce it will ... (FASEB) on July 1, 2013. The FASEB Board approved ... , The 26 constituent societies of FASEB represent more ... the advancement of research and education in biological and ... important now than ever," said Jennifer L. Hunt, MD, ...
(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2The secret of DNA methylation 2
... NEW YORK, Dec. 14, 2010 Reportlinker.com announces that ... catalogue: Global Biochip Markets: Microarrays and ... INTRODUCTION  STUDY GOALS ... study was to determine the status of current and ...
... a severe illness called hemolytic-uremic syndrome (HUS) began in Germany ... people and sickened more than 2,000. The organism causing the ... coli O104:H4 that produces a Shiga toxin and causes ... O157:H7. Two isolates from this outbreak have been sequenced. Both ...
... June 6, 2011. Sustainability is the theme for the ... scheduled to meet in Portland June 19 to 21. ... from academia, government, non-profit groups, and private industry will ... industry and share information about innovations in the field., ...
Cached Biology News:Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15Two isolates from E. coli outbreak available 2
... Introduction of a protein into cells ... cell signaling pathways, apoptotic pathways, and transcription ... for studying the effects of a specific ... transfect the protein directly into the cell. ...
Reacti-Bind DNA Coating Solution...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
... The ProteoExtract™ Protein Precipitation Kit ... up of proteins from aqueous samples. ... by the presence of non-protein impurities ... in the protein sample that interfere ...
Biology Products: